D5D-IN-326

D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice[1].

D5D-IN-326 (Compound-326) is an orally available, potent and selective inhibitor of delta-5 desaturase (D5D) th at reduces insulin resistance and body weight in a high-f at diet-induced obese mice. It appears th at D5D-IN-326 significantly inhibits the progression of atherosclerosis in the aorta of western-diet fed ApoE knockout (KO) mice. It is called Compound-326 in recent J Pharmacol Exp Ther. 2019 Nov;371(2):290-298. (PMID: 31488602) paper.

[1] Yashiro H, et al. A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice. PLoS One. 2016 Nov 10;11(11):e0166198. DOI:10.1371/journal.pone.0166198